+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P04109(MYF5 Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P04109(MYF5 Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

MYF5 (Myogenic Factor 5) is a member of the myogenic regulatory factors (MRFs), a family of transcription factors critical for skeletal muscle development and differentiation. Discovered in the early 1990s, MYF5 is encoded by the *MYF5* gene and plays a pivotal role in myogenesis, particularly during embryonic development. It is expressed early in the commitment of mesodermal precursor cells to the myogenic lineage, working alongside other MRFs like MYOD, myogenin (MYOG), and MRF4 to regulate muscle-specific gene expression. Structurally, MYF5 contains a basic helix-loop-helix (bHLH) domain essential for DNA binding and dimerization with E-proteins to activate target genes.

Antibodies against MYF5 are widely used in research to study muscle cell differentiation, regeneration, and diseases such as muscular dystrophies or rhabdomyosarcoma. These antibodies enable detection of MYF5 protein in various assays, including immunohistochemistry (IHC), Western blotting, and immunofluorescence, helping to identify myogenic progenitors or satellite cells in tissues. MYF5’s expression is often transient and cell-stage-specific, making its antibodies valuable for tracing developmental pathways. However, functional redundancy with other MRFs and overlapping expression patterns in certain contexts require careful experimental validation. Commercially available MYF5 antibodies are typically raised in rabbits or mice, with specificity confirmed using knockout controls. Studies utilizing MYF5 antibodies have significantly advanced understanding of muscle biology, stem cell therapies, and cancer mechanisms involving myogenic deregulation.